Policy dividends continue to be released, and the pharmaceutical retail industry is迎转型新机遇

Recently, policy benefits in the pharmaceutical retail industry have continued to be released, and the pace of transformation and integration upgrades has accelerated. The Ministry of Commerce and eight other departments recently jointly issued the “Opinions on Promoting High-Quality Development of the Pharmaceutical Retail Industry,” introducing a series of support measures focused on industry integration, prescription outflow, and commercial insurance to promote the transformation and upgrading of the pharmaceutical retail industry. Industry insiders say that with policy guidance, market clearing, and model innovation progressing simultaneously, China’s pharmaceutical retail industry is entering a new stage of structural optimization, increased concentration, and restructured profit models. Leading enterprises with scale advantages and integration capabilities will benefit significantly. (China Securities Journal)